5-氯-2-(1-哌嗪基)-嘧啶 | 59215-40-6

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 5-氯-2-(1-哌嗪基)-嘧啶
• 英文名称: 5-chloro-2-(piperazin-1-yl)pyrimidine
• 英文别名: 5-chloro-2-piperazin-1-ylpyrimidine
• CAS: 59215-40-6
• 化学式: C₈H₁₁ClN₄
• 分子量: 198.655
• InChiKey: CNHDTJAPQFANKE-UHFFFAOYSA-N

物化性质

• 沸点：
  362.7±52.0 °C(Predicted)
• 密度：
  1.272±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  41
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  5-氯-2-(1-哌嗪基)-嘧啶 在 sodium tetrahydroborate 、 potassium carbonate 、 potassium iodide 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 36.0h， 生成 4-[4-(5-Chloro-pyrimidin-2-yl)-piperazin-1-yl]-1-(4-fluoro-phenyl)-butan-1-ol
  参考文献：
  名称：

  Synthesis and biological characterization of .alpha.-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogs as potential atypical antipsychotic agents

  摘要：

  A series of 1-(pyrimidin-2-yl)piperazine derivatives were prepared and evaluated in receptor binding assays and in in vivo behavioral paradigms as potential atypical antipsychotic agents. Compound 16 (BMS 181100 (formerly BMY 14802)) emerged as the lead compound from within the series on the basis of its good activity and duration of action in the inhibition of both conditioned avoidance responding and apomorphine-induced stereotopy in the rat. Compound 16 not only failed to induce catalepsy in the rat but was quite effective in reversing the cataleptic effect of neuroleptic agents, thus indicating a low propensity for causing extrapyramidal side effects. In comparison to reference antipsychotic agents, 16 appeared to be less sedating and was relatively weaker in causing muscle incoordination. The compound was essentially inactive in binding to dopamine D2 receptors and its chronic administration to rats did not result in dopamine receptor supersensitivity. It exhibited modest to weak affinity for 5-HT1A and alpha1 receptors but was found to be a fairly potent ligand for sigma binding sites (IC50 vs (+)-[H-3]-3-PPP = 112 nM). Although the resolved enantiomers of racemic 16 did not show dramatic differences from racemate or from each other in most tests, the R(+) enantiomer was up to 11-fold more potent than its antipode in binding to sigma sites. Several studies have indicated that 16 may be a limbic-selective agent which may modulate dopaminergic activity by an indirect mechanism. The compound has been selected for clinical evaluation in the treatment of psychosis.

  DOI：

  10.1021/jm00102a002
• 作为产物：
  描述：

  ethyl 4-(2-pirymidinyl)-1-piperazinecarboxylate 以 盐酸 为溶剂， 生成 5-氯-2-(1-哌嗪基)-嘧啶
  参考文献：
  名称：

  Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives

  摘要：

  二取代N,N-哌嗪基衍生物被披露，其中一个取代基是嘧啶-2-基环，另一个是连接到对氟苯基环的末端碳上的4碳链。这个丁二烯链的末端碳也与一个氧原子结合，作为羰基、醇基或缩醛功能团的一部分。这些化合物具有精神药理特性，特别是良好持续时间的非典型抗精神病活性。通过临床前药理学测试，这些化合物似乎有望作为潜在的抗精神病药物，而不具有标准抗精神病药物的典型运动障碍副作用。

  公开号：

  US04605655A1

文献信息

• PYRIDAZINONES AS PARP7 INHIBITORS
  申请人：Ribon Therapeutics Inc.

  公开号：US20190330194A1

  公开（公告）日：2019-10-31

  The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.

  本发明涉及吡啶并嗪酮和相关化合物，它们是PARP7的抑制剂，并且在癌症治疗中很有用。
• [EN] HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE<br/>[FR] COMPOSÉS HÉTÉROCYCLYLES POUR LE TRAITEMENT D'UNE MALADIE AUTO-IMMUNE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2020064792A1

  公开（公告）日：2020-04-02

  The present invention relates to compounds of formula (I), wherein R1 to R3, A and Q are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

  本发明涉及式(I)的化合物，其中R1至R3，A和Q如本文所述，以及其药学上可接受的盐、对映体或二对映体，以及包括这些化合物的组合物和使用这些化合物的方法。
• [EN] MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL<br/>[FR] MODULATEURS DES RÉCEPTEURS DE LA VASOPRESSINE À POUVOIR THÉRAPEUTIQUE
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2014127350A1

  公开（公告）日：2014-08-21

  Compounds comprising piperazines, piperidines, spiro-furanopiperidines, and analogs thereof are provided that are modulators, such as positive allosteric modulators, of one or more subclasses of vasopressin receptors. The compounds can be selective modulators of one or more subclasses of vasopressin receptors. Compounds of the invention can be used in the treatment of a condition wherein modulating a vasopressin receptor is medically indicated for treatment of the condition.

  提供了包含哌嗪、哌啶、螺环呋喃哌啶及其类似物的化合物，这些化合物是利钠素受体的调节剂，如正向变构调节剂，可以调节一个或多个亚类别的利钠素受体。这些化合物可以是一个或多个亚类别的利钠素受体的选择性调节剂。本发明的化合物可用于治疗需要调节利钠素受体的情况。
• [EN] PYRIDAZINONES AS PARP7 INHIBITORS<br/>[FR] PYRIDAZINONES UTILISÉES EN TANT QU'INHIBITEURS DE PARP7
  申请人：RIBON THERAPEUTICS INC

  公开号：WO2021087018A1

  公开（公告）日：2021-05-06

  The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.

  本发明涉及吡啶并嗪酮和相关化合物，这些化合物是PARP7的抑制剂，并且在癌症治疗中有用。
• Antiparasitic terpene alkaloids
  申请人：Chubb A. Nathan

  公开号：US20070185101A1

  公开（公告）日：2007-08-09

  The present invention relates to novel terpene alkaloids and their use as antiparasitic agents. The present invention also relates to an antiparasitic agent which comprises a terpene alkaloid compound of this invention as an effective ingredient in an, antiparasitic formulation. More particularly, the present invention relates to derivatives of the terpene alkaloid (1S,2R,4aS,5R,8R,8aR)-2-(acetyloxy)-8a-hydroxy-3,8-dimethyl-5-(1-methylethenyl)-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl (2S,3aR,9bR)-6-chloro-9b-hydroxy-5-methyl-1,2,3,3a,5,9b-hexahydropyrrolo[2,3-c][2,1]benzoxazine-2-carboxylate. Pharmaceutical compositions comprising the same are also disclosed.

  本发明涉及新型萜类生物碱及其作为抗寄生虫剂的用途。本发明还涉及一种抗寄生虫剂，其包含本发明中的萜类生物碱化合物作为抗寄生虫制剂中的有效成分。更具体地，本发明涉及萜类生物碱（1S，2R，4aS，5R，8R，8aR）-2-（乙酰氧基）-8a-羟基-3，8-二甲基-5-（1-甲基乙烯基）-1,2,4a,5,6,7,8,8a-八氢萘-1-基（2S，3aR，9bR）-6-氯-9b-羟基-5-甲基-1,2,3,3a,5,9b-六氢吡咯[2,3-c] [2,1]苯并噁唑-2-羧酸酯的衍生物。还公开了包含该物质的药物组合物。